drugset

drugset / Trial / NCT06077656

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

NCT06077656 ↗

Phase 2 Completed 220 enrolled Inventprise Inc. Canadian Center for Vaccinology · collab PATH · collab Vaccine Evaluation Center, Canada · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

Timeline

Start: 2023-10-25
Primary completion: 2024-05-24
Completion: 2024-05-24

Publications

Langley JM, Sadarangani M, Ockenhouse C, Barreto L, Ye L, Tang Y, Breeze JL, Feser J, Hosken NA, Andi-Lolo I, Tasker SA, Halperin SA; Canadian Immunization Research Network. Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials. Vaccine. 2026 Mar 7;75:128236. doi: 10.1016/j.vaccine.2026.128236. Epub 2026 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IVT PCV-25 Formulation A	Unknown	0.5 ml	Intramuscular
Subject	IVT PCV-25 Formulation B	Unknown	0.5 ml	Intramuscular
Subject	IVT PCV-25 Formulation C	Unknown	0.5 ml	Intramuscular
Comparator	PCV20	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.